La chaîne d'options affiche les données clés des options sur actions de Enliven Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Enliven Therapeutics..

Enliven Therapeutics (NASDAQ:ELVN) Stock, Chaîne d'Options

Enliven Therapeutics

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics Inc

Baird analyst Colleen Kusy maintains Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Outperform and raises the price target from $32 to $40.

News

Price Target

Analyst Ratings

ELVN

Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40

Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.49) by 2.04 percent.

Earnings

Earnings Beats

Enliven Therapeutics Q3 2024 GAAP EPS $(0.48) Beats $(0.49) Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Brian Skorney initiated coverage on Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with an Outperform rating and announced a price target of $25. Alumis shares closed at $11.23 on Wednesday. <a href="https://www.benzinga.com/quote/alms/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jones Trading analyst Soumit Roy initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy rating and announced a price target of $36. Enliven Therapeutics shares closed at $28.39 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See</a><a href="https://www.benzinga.com/quote/ELVN/analyst-ratings"> </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Swayampakula Ramakanth initiated coverage on Intensity Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) with a Buy rating and announced a price target of $5. Intensity Therapeutics shares closed at $3.05 on Wednesday. <a href="https://www.benzinga.com/quote/INTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer analyst Jay Olson initiated coverage on Terns Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) with an Outperform rating and announced a price target of $17. Terns Pharma shares closed at $6.89 on Wednesday. <a href="https://www.benzinga.com/quote/TERN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie initiated coverage on Braze, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Neutral rating and announced a price target of $30. Braze shares closed at $32.00 on Wednesday. <a href="https://www.benzinga.com/quote/BRZE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ALMS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="495" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31113725/image-328-1024x495.png" alt="" class="wp-image-624229" style="width:550px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31113725/image-328-1024x495.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31113725/image-328-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31113725/image-328-768x371.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31113725/image-328.png 1238w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>

Initiation

Markets

Trading Ideas

ALMS

BRZE

INTS

TERN

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Jones Trading analyst Soumit Roy initiates coverage on Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy rating and announces Price Target of $36.

Jones Trading Initiates Coverage On Enliven Therapeutics with Buy Rating, Announces Price Target of $36

Most of us have heard the dictum &quot;the trend is your friend.&quot; And this is undeniably the key to success when it comes to short-term investing or trading. But it isn&#39;t easy to ensure the sustainability of a trend and profit from it.
Often, the direction of a stock&#39;s price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it&#39;s important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going.
Investors looking to make a profit from stocks that are currently on the move may find our &quot;Recent Price Strength&quot; screen pretty useful. This predefined screen comes handy in spotting stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
<h2>Enliven Therapeutics, Inc.</h2>
(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elvn#NASDAQ">ELVN</a>) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for &quot;trend&quot; investors.
A solid price increase over a period of 12 weeks reflects investors&#39; continued willingness to pay more for the potential upside in a stock. ELVN is quite a good fit in this regard, gaining 26.8% over this period.
However, it&#39;s not enough to look at the price change for around three months, as it doesn&#39;t reflect any trend reversal that might have happened in a shorter time frame. It&#39;s important for a potential winner to maintain the price trend. A price increase of 25.1% over the past four weeks ensures that the trend is still in place for the stock of this company.
Moreover, ELVN is currently trading at 96.2% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock&#39;s near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.
Another factor that confirms the company&#39;s fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock&#39;s near-term price performance.
So, the price trend in ELVN may not reverse anytime soon.
<a href="https://www.zacks.com/stock/news/2349711/enliven-therapeutics-inc-elvn-is-a-great-choice-for-trend-investors-here-s-why?cid=CS-BENZ-FT-tale_of_the_tape|recent_price_strength_screen-2349711">To read this article on Zacks.com click here.</a>

Biotech

Small Cap

General

Enliven Therapeutics, Inc. Is a Great Choice for 'Trend' Investors, Here's Why

HC Wainwright &amp; Co. analyst Robert Burns reiterates Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy and maintains $37 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Enliven Therapeutics, Maintains $37 Price Target

Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference &nbsp;
Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs
ELVN-001 remains well-tolerated with no dose reductions reported&nbsp;with 39 patients enrolled and a median treatment duration of 20 weeks at cutoff
BOULDER, Colo., Sept. 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, positive data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that has failed, or the patient is intolerant to or not a candidate for, available therapies known to be active for treatment of their CML (<a href="https://www.globenewswire.com/Tracker?data=7W5qBB0cMOZ3r3yHQ7lQqZKIjvg_18OVCDoV-Kb0LpJ3hpeCkVBbk0obODJZVX9ox2u3bkgl6VCVJxYSUcxpNL643m__t8O6CyJ1jsVsEl-3GjPDcAGESnmY1BuFwZGVdiAfqYOm0cYyqgS6CnLinw==">NCT05304377</a>) at the European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference.
ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with CML.

Enliven Therapeutics Announces Data Update From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia; Reported Cumulative MMR Rate Of 44% (8/18) By 24 Weeks, With Stable Or Deepening Responses Between Weeks 12 And 24, Which Continues To Compare Favorably To Precedent Phase 1 Trials Of Approved BCR::ABL1 TKIs

WIIM

Enliven Therapeutics shares are trading higher after the company provided more details regarding the presentation of its updated ELVN-001 Phase1a data of ESH-iCML at the 26th annual John Goldman Conference on CML.

Enliven Therapeutics Announces Details Regarding Presentation Of Updated ELVN-001 Phase 1a Data As ESH-iCMLf 26th Annual John Goldman Conference On CML

HC Wainwright initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) and noted the company as an emerging biotech company developing next-gen precision-oriented small molecules for solid and <a target="_blank" href="https://www.benzinga.com/quote/ELVN" rel="noreferrer noopener">liquid tumor indications</a>.
Enliven&#8217;s pipeline includes:
<ul>
<li>ELVN-001— a tyrosine kinase inhibitor (TKI) targeting mutant BCR::ABL. HC Wainwright highlights that ELVN-001 could meaningfully improve on existing TKI drugs used in chronic myelogenous leukemia, with applicability across multiple lines of therapy.</li>
<li>In April, the company released proof of concept data from the Phase 1 trial of ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or <a href="https://www.benzinga.com/general/biotech/24/04/38208363/enliven-therapeutics-shares-first-look-at-safety-clinical-activity-of-lead-program" target="_blank" rel="noreferrer noopener">intolerant to available TKIs</a>.</li>
<li>ELVN-001 achieved a cumulative major molecular response (MMR) rate of 44% (7/16) by 12 weeks and demonstrated responses in patients with prior exposure to asciminib and who were TKI-resistant.</li>
<li>ELVN-002 is being evaluated in combination with trastuzumab plus chemotherapy or as monotherapy in HER2-driven malignancies within non-small cell lung, colorectal, and metastatic breast cancer, among others.</li>
</ul>
The analyst initiates with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/ELVN/analyst-ratings" rel="noreferrer noopener">price target of $37</a>.
CML is a chronic disease requiring multiple years of continuous treatment. Patients frequently switch therapies due to liabilities of the existing approved drugs, including poor tolerability due to off-target effects and inability to dose to maximal efficacy.
Six approved drugs—Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Gleevec (imatinib), Scemblix (asciminib), and Tasigna (nilotinib), Bristol-Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Sprycel (dasatinib), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Bosulif (bosutinib), and Takeda Pharmaceutical Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) Iclusig (ponatinib)—generate over $6 billion in annual sales, with each drug bringing in around $500 million. Some even achieve peak annual sales of up to $2 billion despite competition from generic versions.
HC Wainwright analyst projects that positioning ELVN-001 as a third-line treatment could surpass $500 million in peak annual sales.
ELVN-002 has the potential to address unmet needs in HER2-mutant NSCLC, CRC, and mBC, where current treatments have limitations. It could challenge competitors like Pfizer&#8217;s Tukysa and tap into the growing post-AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Enhertu market, with sales possibly reaching hundreds of millions.
While Enliven focuses on precision oncology, its target market is broader than that of past agents like Bristol-Myers&#8217; Augtyro (repotrectinib) and Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Rozlytrek (entrectinib).
Price Action: ELVN stock is up 7.32% at $23.01 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40778617/cytokinetics-sets-stage-for-mid-stage-study-for-heart-failure-drug-after-encouraging-data-from-ph" target="_blank" rel="noreferrer noopener">Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study</a>.</li>
</ul>

Health Care

Movers

RHHBY

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst

HC Wainwright &amp; Co. analyst Robert Burns initiates coverage on Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy rating and announces Price Target of $37.

HC Wainwright & Co. Initiates Coverage On Enliven Therapeutics with Buy Rating, Announces Price Target of $37

Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.55) by 25.45 percent. This is unchanged from the same period last year.

Enliven Therapeutics Q2 EPS $(0.41) Beats $(0.55) Estimate

Baird analyst Colleen Kusy initiates coverage on Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Outperform rating and announces Price Target of $32.

Baird Initiates Coverage On Enliven Therapeutics with Outperform Rating, Announces Price Target of $32

Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.57) by 5.26 percent.

Enliven Therapeutics Q1 2024 Adj EPS $(0.54) Beats $(0.57) Estimate

Thursday,&nbsp;Enliven Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) released proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38199613/enliven-therapeutics-announces-positive-proof-of-concept-data-from-phase-1-clinical-trial-of-elvn-" rel="noreferrer noopener">tyrosine kinase inhibitors (TKIs)</a>.
ELVN-001 is a small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with CML.
&#8220;We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,&#8221; said Helen Collins, Chief Medical Officer of Enliven.&nbsp;
Related Content:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38170122/enliven-therapeutics-well-positioned-with-conservative-trading-levels-analyst-says" rel="noreferrer noopener">Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says</a>.
As of the cutoff date, March 18, 2024, 27 patients had enrolled in the ongoing Phase 1 clinical trial across five dose levels of ELVN-001, ranging from 10mg once daily (QD) to 120mg QD.&nbsp;
ELVN-001 achieved a cumulative major molecular response (MMR) rate of 44% (7/16) by 12 weeks and demonstrated responses in patients with prior exposure to asciminib and who were TKI-resistant:
Among response-evaluable patients, all had improved or stable BCR::ABL1 transcript levels by 12 weeks.
ELVN-001 has been well tolerated, consistent with its selective kinase profile, with no ≥ Grade 3 treatment-related non-hematologic toxicities reported.
A maximum tolerated dose has not been identified, and there have been no dose reductions.
ELVN-001&#8217;s PK profile supports once-daily dosing with flexible administration requirements (no significant food effect and minimal risk of drug-drug interactions).
Price Action:&nbsp;ELVN shares are up 23.60% at $24.50 on the last check Thursday.

Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program

Shares of Fastenal Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fast#NASDAQ">FAST</a>) fell sharply during Thursday&rsquo;s session following worse-than-expected first-quarter financial results.
Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company&#39;s first-quarter EPS was 52 cents, missing the consensus of 53 cents.
Fastenal shares dipped 6.7% to $69.73 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Rallybio Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rlyb#NASDAQ">RLYB</a>) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson &amp; Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.</li>
<li>Rent the Runway, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rent#NASDAQ">RENT</a>) shares jumped 74.5% to $12.91 after the company reported mixed fourth-quarter financial results and issued guidance.</li>
<li>Eliem Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elym#NASDAQ">ELYM</a>) jumped 59.6% to $4.2650. The company announced that it entered into a definitive acquisition agreement to acquire Tenet and it also entered into a securities purchase agreement for a $120 million private placement.</li>
<li>Akanda Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akan#NASDAQ">AKAN</a>) gained 36% to $0.1632. Akanda, last month, announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry.</li>
<li>Alpine Immune Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alpn#NASDAQ">ALPN</a>) rose 36.6% to $64.25 after Vertex entered into an agreement to acquire the company.</li>
<li>Candel Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cadl#NASDAQ">CADL</a>) surged 29.6% to $6.61 after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer.</li>
<li>Enliven Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elvn#NASDAQ">ELVN</a>) gained 26% to $24.97. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.</li>
<li>Selina Hospitality PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slna#NASDAQ">SLNA</a>) rose 21.1% to $0.0923.</li>
<li>Globavend Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gvh#NASDAQ">GVH</a>) climbed 16.8% to $1.68.</li>
<li>Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) gained 16.8% to $52.15 following Wednesday reports suggesting the company is said to weigh a possible sale.</li>
<li>SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) shares rose 15.3% to $1.9357.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) gained 14.6% to $15.91.</li>
<li>AnaptysBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anab#NASDAQ">ANAB</a>) climbed 11.4% to $24.72. Wells Fargo analyst Derek Archila initiated coverage on AnaptysBio with an Overweight rating and announced a price target of $56.</li>
<li>Verb Technology Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verb#NASDAQ">VERB</a>) gained 10.4% to $0.2010 after gaining 4% on Wednesday.</li>
<li>GigaCloud Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gct#NASDAQ">GCT</a>) rose 10.2% to $34.18.</li>
<li>Nurix Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrix#NASDAQ">NRIX</a>) gained 9.6% to $17.21. Baird analyst Joel Beatty maintained Nurix Therapeutics with an Outperform and raised the price target from $24 to $25.</li>
<li>StepStone Group LP (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/step#NASDAQ">STEP</a>) rose 7.1% to $37.46 after JP Morgan upgraded the stock from Neutral to Overweight.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aptevo Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apvo#NASDAQ">APVO</a>) shares fell 58% to $1.01 after the company priced its $4.6 million public offering.</li>
<li>Enlivex Therapeutics Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/enlv#NASDAQ">ENLV</a>) fell 54.5% to $1.81. The company announced topline results of its Phase II trial evaluating Allocetra in sepsis.</li>
<li>AVITA Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcel#NASDAQ">RCEL</a>) fell 28.6% to $10.31 after the company announced an update to its expected commercial revenue for the first quarter of 2024. BTIG downgraded the stock from Buy to Neutral.</li>
<li>Aesthetic Medical International Holdings Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aih#NASDAQ">AIH</a>) fell 19% to $0.3723.</li>
<li>Globe Life Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gl#NYSE">GL</a>) fell 14.6% to $89.65.</li>
<li>The Lovesac Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/love#NASDAQ">LOVE</a>) shares fell 14.3% to $20.00 after the company reported worse-than-expected fourth-quarter results and issued first-quarter guidance.</li>
<li>Globe Life Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gl#NYSE">GL</a>) fell 13.7% to $90.56.</li>
<li>Meiwu Technology Company Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wnw#NASDAQ">WNW</a>) shares declined 12.4% to $1.1601 after jumping around 32% on Wednesday.</li>
<li>Acorda Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acor#NASDAQ">ACOR</a>) fell 12% to $0.7660 after declining 14% on Wednesday. Acorda Therapeutics recently commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code.</li>
<li>CarMax, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kmx#NYSE">KMX</a>) fell 11.7% to $70.02 after the company reported lower-than-expected fourth-quarter earnings.</li>
<li>VBI Vaccines Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vbiv#NASDAQ">VBIV</a>) dipped 11.3% to $0.5641.</li>
<li>Nikola Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkla#NASDAQ">NKLA</a>) fell 11.3% to $0.8680. On April 9, Wolfe Research analyst Scott Group initiated coverage on Nikola with a Peer Perform rating.</li>
<li>Marin Software Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrin#NASDAQ">MRIN</a>) declined 10.8% to $0.5798.</li>
<li>SolarBank Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/suun#NASDAQ">SUUN</a>) fell 9.3% to $5.29. SolarBank closed purchase of 3.15 MW solar project in New York from Storke Renewable.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) fell 9.1% to $2.29.</li>
<li>9F Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfu#NASDAQ">JFU</a>) fell 8.8% to $2.7046.</li>
<li>iCoreConnect Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icct#NASDAQ">ICCT</a>) shares fell 8.5% to $1.55 after jumping over 50% on Wednesday.</li>
<li>ClearOne, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clro#NASDAQ">CLRO</a>) declined 8.3% to $1.00. The company recently reported fourth-quarter financial results.</li>
<li>Nyxoah S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nyxh#NASDAQ">NYXH</a>) fell 7.3% to $9.83</li>
<li>Acorda Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acor#NASDAQ">ACOR</a>) fell 6.2% to $0.8164.</li>
<li>Walker &amp; Dunlop, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wd#NYSE">WD</a>) fell 5.3% to $87.71 after Wedbush downgraded the stock from Outperform to Neutral and lowered its price target from $130 to $95.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38200890/top-3-health-care-stocks-which-could-rescue-your-portfolio-this-quarter"> Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter</a>

Penny Stocks

Intraday Update

ACOR

AKAN

ALPN

ANAB

APVO

CADL

CLRO

ELYM

ENLV

ESPR

FAST

GYRE

ICCT

JANX

LOVE

MRIN

NKLA

NRIX

NYXH

RCEL

RENT

RLYB

SLNA

SPRC

STEP

SUUN

VBIV

VERB

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Enliven Therapeutics shares are trading higher after the company announced proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia.

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday.
Shares of Enliven Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elvn#NASDAQ">ELVN</a>) rose sharply during Thursday&rsquo;s session.
Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in <a href="https://www.benzinga.com/general/biotech/24/04/38199756/enliven-therapeutics-announces-proof-of-concept-data-from-phase-1-clinical-trial-of-elvn-001-in-c">chronic myeloid leukemia</a>.
Enliven Therapeutics shares surged 26% to $24.97 on Thursday.
Here are some other big stocks recording losses in today&rsquo;s session.
<ul>
<li>Rallybio Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rlyb#NASDAQ">RLYB</a>) shares gained 89.6% to $3.09 after the company announced a collaboration with Johnson &amp; Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.</li>
<li>Alpine Immune Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alpn#NASDAQ">ALPN</a>) jumped 36.6% to $64.25 after Vertex entered into an agreement to acquire the company.</li>
<li>Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) shares jumped 16.8% to $52.15 following Wednesday reports suggesting the company is said to weigh a possible sale.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) rose 14.6% to $15.91.</li>
<li>AnaptysBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anab#NASDAQ">ANAB</a>) rose 11.4% to $24.72. Wells Fargo analyst Derek Archila initiated coverage on AnaptysBio with an Overweight rating and announced a price target of $56.</li>
<li>Fiverr International Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fvrr#NYSE">FVRR</a>) gained 10.5% to $21.25 after the company&#39;s board authorized a $100 million share repurchase program.</li>
<li>GigaCloud Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gct#NASDAQ">GCT</a>) shares jumped 10.2% to $34.18.</li>
<li>Nurix Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrix#NASDAQ">NRIX</a>) climbed 9.6% to $17.21. Baird analyst Joel Beatty maintained Nurix Therapeutics with an Outperform and raised the price target from $24 to $25.</li>
<li>AlTi Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alti#NASDAQ">ALTI</a>) gained 9.3% to $5.06.</li>
<li>Nexxen International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexn#NASDAQ">NEXN</a>) rose 7.3% to $5.62.</li>
<li>StepStone Group LP (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/step#NASDAQ">STEP</a>) gained 7.1% to $37.46 after JP Morgan upgraded the stock from Neutral to Overweight.</li>
<li>Frontline plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fro#NYSE">FRO</a>) rose 5.9% to $24.47.</li>
<li>IAMGOLD Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iag#NYSE">IAG</a>) gained 3.6% to $3.74.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/04/38200324/dell-designer-brands-and-2-other-stocks-insiders-are-selling"> Dell, Designer Brands And 2 Other Stocks Insiders Are Selling</a>

ALTI

FVRR

NEXN

Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs &nbsp;
Achieved initial cumulative MMR rate of 44% (4/9) by 12 weeks in response-evaluable patients who were previously treated with asciminib
ELVN-001 was well tolerated with no&nbsp;≥&nbsp;Grade 3 treatment-related non-hematologic toxicities reported&nbsp;
Company to host virtual event with Key Opinion Leaders at 8:00 AM ET Today
BOULDER, Colo., April 11, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced positive proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs) (<a href="https://www.globenewswire.com/Tracker?data=DjkD3g4U3_UqeAgyaWYVEr0PiFaIia9z1i78YT_W8qSB_9ttyCt-5Q-NCtbAyDn6B5vg9ujed_H_DJv6_DEnc0PbzoTyBgz0u1P2-ulLwLVWx8WgofmTM6LFgDgnbff5G1DQjkJP8fa9dGMy6gFnBQ==">NCT05304377</a>).
ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with CML.
"Significant advancements have been made over the past few decades for patients with CML, and the approved TKIs provide important treatment options for patients with CML. However, there are limitations with the available therapies, including intolerance or resistance, that result in inadequate target coverage, the loss of molecular response and disease progression in many patients," said presenting investigator Fabian Lang, M.D., from Goethe University Hospital. "Similar to our experience with previous successful Phase 1 trials in CML, ELVN-001 looks promising. The preliminary data support that ELVN-001 is a potent and highly selective BCR::ABL1 inhibitor that has activity in heavily pre-treated patients, including post-asciminib patients."
"We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs," said Helen Collins, M.D., Chief Medical Officer of Enliven. "Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm."
Patient Demographics
<ul>
<li>As of the cutoff date, March 18, 2024, 27 patients had enrolled in the ongoing Phase 1 clinical trial across five dose levels of ELVN-001, ranging from 10mg once daily (QD) to 120mg QD. Of the enrolled patients, 16 were evaluable for molecular response by 12 weeks.</li>
<li>Patients enrolled were heavily pretreated:
<ul>
<li>70% of patients had ≥ 3 prior TKIs.</li>
<li>70% of patients had received prior ponatinib and/or prior asciminib.</li>
<li>67% of patients had discontinued their last prior TKI due to lack of efficacy. &nbsp;</li>
</ul>
</li>
</ul>
Preliminary Efficacy
<ul>
<li>ELVN-001 achieved a cumulative major molecular response (MMR) rate of 44% (7/16) by 12 weeks and demonstrated responses in patients with prior exposure to asciminib and/or who were TKI-resistant:
<ul>
<li>Among post-asciminib patients, ELVN-001 achieved a cumulative MMR rate of 44% (4/9) by 12 weeks.</li>
<li>Among TKI-resistant patients, ELVN-001 achieved a cumulative MMR rate of 40% (4/10) by 12 weeks.</li>
</ul>
</li>
<li>Among response-evaluable patients, all had improved or stable BCR::ABL1 transcript levels by 12 weeks.</li>
<li>These data compare favorably to precedent Phase 1 cumulative MMR rates for approved BCR::ABL1 TKIs, particularly given the shorter time frame for response assessment and a more heavily pre-treated patient population. &nbsp;</li>
</ul>
Preliminary Safety
<ul>
<li>ELVN-001 has been well tolerated, consistent with its selective kinase profile.</li>
<li>A maximum tolerated dose has not been identified, and there have been no dose reductions.</li>
<li>No ≥ Grade 3 non-hematologic treatment-related adverse events (TRAE) and no specific non-hematologic TRAE of any grade occurred in &gt;11% of patients.</li>
<li>Hematologic adverse events observed are consistent with the approved BCR::ABL1 TKIs.</li>
</ul>
Pharmacokinetics (PK) &amp; Target Coverage
<ul>
<li>ELVN-001's PK profile supports once daily dosing with flexible administration requirements (no significant food effect and minimal risk of drug-drug interactions).</li>
<li>Importantly, given the strong correlation between target coverage and 1L efficacy for the approved BCR::ABL1 TKIs,
<ul>
<li>ELVN-001, at doses equal to or greater than 40mg QD, achieved superior target coverage compared to 2nd Generation, active-site TKIs.</li>
<li>ELVN-001, at 80mg QD, achieved similar target coverage compared to asciminib.</li>
</ul>
</li>
</ul>
"We are thrilled with ELVN-001's initial Phase 1 data in heavily pre-treated patients with CML," said Sam Kintz, Co-founder and Chief Executive Officer of Enliven. "We believe that with the data presented today, ELVN-001 has initially addressed each key area of our target product profile. Given our expectation that asciminib [Scemblix] will soon become an important standard of care in the early-line CML setting, we hope to initially position ELVN-001 as the best-in-class active-site BCR::ABL1 TKI. We believe that ELVN-001's initial cumulative MMR rate, including in post-asciminib patients, and its tolerability profile are supportive of this positioning. These data are supported by ELVN-001's pharmacokinetic data, which showed superior target coverage at doses equal to or greater than 40mg QD compared to 1st and 2nd Generation TKIs. Finally, and most importantly, we recognize that this achievement is made possible by the patients, caregivers, and investigators who are participating in the ELVN-001 trial, and we offer them our sincere gratitude."
Company Event with Investigators and Key Opinion Leaders (KOLs)
Enliven is hosting a company event with KOLs today at 8:00 AM ET. The event will feature leading CML investigators and hematology care experts, Michael Mauro, M.D., from Memorial Sloan Kettering Cancer Center, and Fabian Lang, M.D., from Goethe University Hospital, along with the management of Enliven Therapeutics. The discussion will cover details of ELVN-001's Phase 1 initial proof of concept data, the evolving treatment paradigm in CML, and how ELVN-001 could fit into the CML landscape.
The event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at <a href="https://ir.enliventherapeutics.com/">https://ir.enliventherapeutics.com</a>. To participate in the live event, please register using this <a href="https://www.globenewswire.com/Tracker?data=eg8ZqwLfEtVcZSAhDa8iymeZfmuBVk_m2OJpj4EZaXWfflGi6phDZTDfjZfn0k9Um4VSrucBlnnbCRKQ36M9BwsFbsI6sMutpFFZv_g2qVQFj2e2HJGmZSUwd1paz1CO">link</a>. An archived webcast will be available following the event.
About the Phase 1 ELVN-001 Trial
The Phase 1 clinical trial of ELVN-001 is a dose escalation trial designed to evaluate the safety and tolerability, and determine the recommended dose for further clinical evaluation of, ELVN-001 in patients with CML with and without T315I mutations who are relapsed, refractory or intolerant to TKIs. The primary endpoint of the study is safety. Secondary endpoints include pharmacokinetics, MMR by central qPCR, duration of MMR, BCR::ABL1 transcript levels and complete hematologic response.
About ELVN-001
ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. As a highly selective active site inhibitor, ELVN-001 has a mechanism of action that is complementary to allosteric BCR::ABL1 inhibitors, which may play an increasingly important role in the standard of care. ELVN-001 was also designed to have activity against the T315I mutation, the most common BCR::ABL1 mutation, which confers resistance to nearly all approved TKIs as well as activity against mutations known to confer resistance to allosteric BCR::ABL1 inhibitors.

Enliven Therapeutics Announces Proof Of Concept Data From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia

Mizuho Securities&nbsp;initiated coverage on&nbsp;Enliven Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>), a clinical-stage precision oncology company focused on discovering and developing next-generation small molecule kinase inhibitors.
The company&#8217;s lead product, ELVN-001, is under development for Chronic myelogenous leukemia (CML), a slow-progressing blood cancer that begins in the bone marrow.
Thursday, Enliven Therapeutics will host a webcast to discuss initial proof of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37994181/enliven-therapeutics-to-share-initial-proof-of-concept-data-from-phase-1-clinical-trial-of-elvn-00" rel="noreferrer noopener">concept data on ELVN-001</a>.
Additional Phase 1 data is expected in 2025, but Mizuho expects late 2024 could also be possible.
Mizuho writes that the CML tyrosine kinase inhibitors (TKI) market is established, ~$13 billion-$14 billion worldwide, and it has been growing since 2001 when&nbsp;Novartis AG&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Gleevec (imatinib) became the first TKI to receive regulatory approval.&nbsp;
Over the last two decades, there have been four generations of TKIs approved for this disease.&nbsp;
However, approved TKIs are still limited in their design and, therefore, still produce various safety/tolerability issues.&nbsp;
The analyst writes that Enliven is well-positioned to address these shortcomings, and if it succeeds in doing so, this should garner an alpha opportunity for investors.&nbsp;
Mizuho initiates with a Buy rating and a&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/ELVN/analyst-ratings" rel="noreferrer noopener">price target of $34</a>.
Mizuho says that in the past two decades, even the least successful CML TKI has consistently generated at least $500 million in sales at its peak.&nbsp;
Additionally, the prevalence of CML is increasing, with the global market currently valued at around $13-14 billion in branded sales.&nbsp;
Considering this, the current trading value of ELVN, at around 1x its projected minimum peak sales in this market, appears to be quite conservative.&nbsp;
Typically, investors are comfortable with multiples of 2-4x the expected peak sales for biotech companies showing growth potential. Therefore, the trading levels for ELVN-001 seem cautious.
Price Action: ELVN shares are up 3.72% at $18.98 on the last check Tuesday.
Illustration of Phrama lab worker created with MidJourney

Analyst Color

Equities

Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Demant (WILLF – Research Report) and Enliven Therapeutics (ELVN –...

Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Enliven Therapeutics (ELVN)

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Enliven Therapeutics (ELVN – Research Report). The company's share...

TD Cowen Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enliven Therapeutics (ELVN – Research Report), Harmo...

Analysts Are Bullish on These Healthcare Stocks: Enliven Therapeutics (ELVN), Harmony Biosciences Holdings (HRMY)

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on ELVN stock, giving a Buy rating yesterday. Robert Burns has given his B...

Enliven Therapeutics Garners Buy Rating on Robust Clinical Results and Safety Profile for Lead CML Drug Candidate

Robert W. Baird analyst Colleen M. Kusy has reiterated their bullish stance on ELVN stock, giving a Buy rating on October 1. Colleen M. Kusy's rati...

Outperform Rating for Enliven Therapeutics' ELVN-001 Based on Strong Efficacy and Safety Profile in CML Treatment

Enliven Therapeutics GAAP EPS of -$0.48 beats by $0.02

TD Cowen analyst Phil Nadeau has maintained their bullish stance on ELVN stock, giving a Buy rating on October 30. Phil Nadeau has given his Buy ra...

Enliven Therapeutics: Promising Clinical Developments and Robust Financial Position Justify Buy Rating

JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating today. Soumit Roy has given his Buy rating d...

Promising Clinical Developments and Strategic Positioning Drive Buy Rating for Enliven Therapeutics

Enliven Therapeutics (ELVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky fro...

Enliven Therapeutics: Strategic Positioning and Promising Developments Justify Buy Rating

Enliven Therapeutics, Inc. ( ($ELVN) ) has released its Q3 earnings. Here is a breakdown of the information Enliven Therapeutics, Inc. presented to...

Enliven Therapeutics Reports Q3 Results and Clinical Progress

ALKS

HRMY

WILLF

Management

Press Releases

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Comments

Enliven Therapeutics

Enliven Therapeutics (ELVN) Options

Enliven Therapeutics (NASDAQ:ELVN) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL